Very Long-Term (15 to 20 Years) Clinical and Angiographic Outcome After Coronary Bare Metal Stent Implantation
暂无分享,去创建一个
Yoshihisa Nakagawa | Takeshi Arita | Yoshimitsu Soga | Takeshi Morimoto | Kenji Ando | Takeshi Kimura | Katsumi Inoue | M. Nobuyoshi | Takeshi Kimura | T. Morimoto | K. Yamaji | K. Ando | Y. Nakagawa | H. Yokoi | Katsumi Inoue | M. Goya | S. Shirai | Masakiyo Nobuyoshi | Katsuhiro Kondo | M. Iwabuchi | Masahiko Goya | Masashi Iwabuchi | Shinichi Shirai | Koyu Sakai | T. Arita | Kyohei Yamaji | Katsuhiro Kondo | Hiroyoshi Yokoi | Hideyuki Nosaka | Y. Soga | H. Nosaka | Koyu Sakai
[1] Antonio Colombo,et al. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. , 2010, Journal of the American College of Cardiology.
[2] A. Colombo,et al. TAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[3] J. Marco,et al. Nine‐year follow‐up of balloon‐expandable Palmaz‐Schatz stent in patients with single‐vessel disease , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[4] Michael Joner,et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.
[5] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[6] Renu Virmani,et al. Healed Plaque Ruptures and Sudden Coronary Death: Evidence That Subclinical Rupture Has a Role in Plaque Progression , 2001, Circulation.
[7] A. Kirtane,et al. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. , 2009, Journal of the American College of Cardiology.
[8] Y. Hayashi,et al. Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry). , 2010, The American journal of cardiology.
[9] H Yokoi,et al. Three-year follow-up after implantation of metallic coronary-artery stents. , 1996, The New England journal of medicine.
[10] Neville Kukreja,et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.
[11] Patrick W Serruys,et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. , 2007, Journal of the American College of Cardiology.
[12] Renu Virmani,et al. One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. , 2009, JACC. Cardiovascular imaging.
[13] P. Serruys,et al. Long term outcome after coronary stent implantation: a 10 year single centre experience of 1000 patients , 1999, Heart.
[14] C. Varas‐Lorenzo,et al. Clinical and sequential angiographic follow-up six months and 10 years after successful percutaneous transluminal coronary angioplasty. , 1999, The American journal of cardiology.
[15] M. Nobuyoshi,et al. Long-Term Clinical and Angiographic Follow-Up After Coronary Stent Placement in Native Coronary Arteries , 2002, Circulation.
[16] M. Nobuyoshi,et al. Late restenosis of the balloon-dilated site: serial angiographic observations beyond 7 years. , 2005, Circulation journal : official journal of the Japanese Circulation Society.
[17] Hong Wang,et al. Five-year follow up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial , 2009 .
[18] M. Nobuyoshi,et al. Pathological finding of sirolimus-eluting stent (SES) restenosis lesion with black hole appearance on intravascular ultrasound. , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[19] Michio Nakanishi,et al. Pathological analyses of long-term intracoronary Palmaz-Schatz stenting; Is its efficacy permanent? , 2004, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[20] Y. Hayashi,et al. Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation , 2009, Circulation.
[21] G. Guagliumi,et al. Long-term (> or =8 years) outcome after Palmaz-Schatz stent implantation. , 2001, The American journal of cardiology.
[22] S. Shaughnessy,et al. Do No Harm: Health Systems’ Duty to Promote Clinician Well-Being , 2022, American Journal of Hospital Medicine.
[23] John Bresnahan,et al. Outcomes of Stent Thrombosis and Restenosis During Extended Follow-Up of Patients Treated With Bare-Metal Coronary Stents , 2007, Circulation.
[24] Yoshihiko Seino,et al. Appearance of lipid-laden intima and neovascularization after implantation of bare-metal stents extended late-phase observation by intracoronary optical coherence tomography. , 2009, Journal of the American College of Cardiology.
[25] E F Cook,et al. Comparative Reproducibility and Validity of Systems for Assessing Cardiovascular Functional Class: Advantages of a New Specific Activity Scale , 1981, Circulation.